A US cohort study indicated that statin use may reduce the risks of hepatocellular carcinoma (HCC) and progression of chronic liver disease (CLD). The study included 16 501 CLD patients (mean age, 59.7 years, females 40.9%), with 3610 statin users and 12 891 nonusers. Compared with nonusers, statin users exhibited a significantly lower 10-year cumulative incidence of HCC (3.8% vs 8.0%, adjusted subhazard ratio [aSHR] 0.67) and hepatic decompensation (10.6% vs 19.5%, aSHR 0.78). Exposure to lipophilic statins (atorvastatin, fluvastatin, lovastatin, pitavastatin, and simvastatin) and duration of statin use (≥600 cumulative defined daily dose) were associated with further risk reductions in HCC and hepatic decompensation. Among 7038 patients with serial FIB-4 (an index of liver fibrosis) data, patients with intermediate baseline FIB-4 scores, 14.7% of statin users transitioned to the high group compared with 20.0% of nonusers. For patients with high baseline FIB-4 scores, 31.8% of statin users transitioned to the intermediate group and 7.0% transitioned to the low-risk group, compared to 18.8% and 4.3% of nonusers, respectively. The findings suggest that statins might be chemopreventive against HCC and CLD progression. Source: https://jamanetwork.com/
Two recent studies highlight the importance of physical activity volume and intensity in reducing cardiovascular…
A prospective UK cohort study found that both self-reported average or brisk walking pace and…
A U.S. randomized clinical trial found that 4:3 intermittent fasting (IMF) led to slightly greater…
A Danish nationwide cohort study provided real world evidence that both glucagon-like peptide 1 receptor…
A systematic review and meta-analysis of placebo-controlled randomized trials showed that there is moderate certainty…
A US cohort study suggests that carotid artery plaque (CAP) becomes very common with increasing…
This website uses cookies.